Literature DB >> 15052241

Should we be screening for myocardial hibernation in heart failure?

Eric T S Lim, Avijit Lahiri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15052241     DOI： 10.1016/j.nuclcard.2004.01.005

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  18 in total

1.  Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop.

Authors:  R A Kloner; R Bolli; E Marban; L Reinlib; E Braunwald
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

2.  The hibernating myocardium.

Authors:  S H Rahimtoola
Journal:  Am Heart J       Date:  1989-01       Impact factor: 4.749

3.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

4.  Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure.

Authors:  R Senior; S Kaul; A Lahiri
Journal:  J Am Coll Cardiol       Date:  1999-06       Impact factor: 24.094

5.  Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.

Authors:  J He; L G Ogden; L A Bazzano; S Vupputuri; C Loria; P K Whelton
Journal:  Arch Intern Med       Date:  2001-04-09

6.  Prevalence and mortality rate of congestive heart failure in the United States.

Authors:  D D Schocken; M I Arrieta; P E Leaverton; E A Ross
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

7.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

8.  Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.

Authors:  J G F Cleland; D J Pennell; S G Ray; A J Coats; P W Macfarlane; G D Murray; J Dalle Mule; Z Vered; A Lahiri
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

9.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Authors:  A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

Review 10.  The heart failure revascularisation trial (HEART): rationale, design and methodology.

Authors:  J G F Cleland; N Freemantle; S G Ball; R S Bonser; P Camici; S Chattopadhyay; D Dutka; J Eastaugh; J Hampton; S Large; M S Norell; D J Pennell; J Pepper; S Sanda; R Senior; D Smith
Journal:  Eur J Heart Fail       Date:  2003-06       Impact factor: 15.534
View more
  1 in total

Review 1.  Radionuclide imaging of cardiac autonomic innervation.

Authors:  Sang Yong Ji; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.